These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 9376555)
21. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222 [TBL] [Abstract][Full Text] [Related]
22. Effect of superparamagnetic iron oxide on tumor-to-liver contrast at T2*-weighted gradient-echo MRI: comparison between 3.0T and 1.5T MR systems. Kim T; Murakami T; Hori M; Onishi H; Tomoda K; Nakamura H J Magn Reson Imaging; 2009 Mar; 29(3):595-600. PubMed ID: 19243054 [TBL] [Abstract][Full Text] [Related]
23. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184 [TBL] [Abstract][Full Text] [Related]
24. Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Kim YK; Han YM; Kim CS Eur J Radiol; 2009 Apr; 70(1):94-100. PubMed ID: 18316169 [TBL] [Abstract][Full Text] [Related]
25. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium]. Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542 [TBL] [Abstract][Full Text] [Related]
26. Alterations in hepatic uptake and distribution of organ-specific superparamagnetic MRI contrast media: clinical findings and classification according to pathogenesis. Macarini L; Marini S; Murrone M; Ettorre GC Radiol Med; 2004; 108(1-2):92-106. PubMed ID: 15269693 [TBL] [Abstract][Full Text] [Related]
27. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. Mori K; Yoshioka H; Itai Y; Okamoto Y; Mori H; Takahashi N; Saida Y AJR Am J Roentgenol; 2000 Dec; 175(6):1659-64. PubMed ID: 11090400 [TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317 [TBL] [Abstract][Full Text] [Related]
29. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of small (Tonan T; Fujimoto K; Azuma S; Ono N; Matsushita S; Kojiro M; Hayabuchi N Eur J Radiol; 2007 Oct; 64(1):133-9. PubMed ID: 17408900 [TBL] [Abstract][Full Text] [Related]
31. Malignant hepatic tumor detection with ferumoxides-enhanced MR imaging with a 1.5-T system: comparison of four imaging pulse sequences. Kanematsu M; Itoh K; Matsuo M; Maetani Y; Ametani F; Kondo H; Kato H; Hoshi H J Magn Reson Imaging; 2001 Feb; 13(2):249-57. PubMed ID: 11169831 [TBL] [Abstract][Full Text] [Related]
32. [The value of the liver-specific superparamagnetic contrast medium AMI-25 for the detection and differential diagnosis of primary liver tumors versus metastases]. Vogl TJ; Hammerstingl R; Pegios W; Hamm B; Eibl-Eibesfeldt A; Woessmer B; Lissner J; Felix R Rofo; 1994 Apr; 160(4):319-28. PubMed ID: 8161744 [TBL] [Abstract][Full Text] [Related]
33. Detection of focal liver lesions with superparamagnetic iron oxide: value of STIR and SE imaging. Halavaara JT; Lamminen AE; Bondestam S; Standertskjöld-Nordenstam CG; Hamberg LM J Comput Assist Tomogr; 1994; 18(6):897-904. PubMed ID: 7962796 [TBL] [Abstract][Full Text] [Related]
34. Detection of hepatocellular carcinoma and its metastases with various pulse sequences using superparamagnetic iron oxide (SHU-555-A). Arbab AS; Ichikawa T; Araki T; Toyama K; Nambu A; Ohsawa S; Kumagai H; Aikawa Y Abdom Imaging; 2000; 25(2):151-8. PubMed ID: 10675457 [TBL] [Abstract][Full Text] [Related]
35. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. Grangier C; Tourniaire J; Mentha G; Schiau R; Howarth N; Chachuat A; Grossholz M; Terrier F J Comput Assist Tomogr; 1994; 18(6):888-96. PubMed ID: 7962795 [TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Hatanaka Y; Murakami R; Nishiharu T; Takahashi M; Higashida Y; Moribe N Radiology; 1995 Apr; 195(1):106-12. PubMed ID: 7892448 [TBL] [Abstract][Full Text] [Related]
37. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases]. Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693 [TBL] [Abstract][Full Text] [Related]
38. Malignant hepatic tumor detection with ferumoxide-enhanced magnetic resonance imaging: is chemical-shift-selective fat suppression necessary for fast spin-echo sequence? Goshima S; Kanematsu M; Matsuo M; Kondo H; Kako N; Yokoyama R; Hoshi H; Moriyama N J Magn Reson Imaging; 2004 Jul; 20(1):75-82. PubMed ID: 15221811 [TBL] [Abstract][Full Text] [Related]
39. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media]. Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882 [TBL] [Abstract][Full Text] [Related]
40. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient. Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]